A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China

Documenti analoghi

• Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
  di: Othman Salim Akhtar, et al.
  Pubblicazione: (2024)
• Dynamic risk prediction model for multiple myeloma
  di: Mary Beth Nierengarten
  Pubblicazione: (2024)
• Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression
  di: Wataru Kuroki, et al.
  Pubblicazione: (2025)
• Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma
  di: Xiang Liu, et al.
  Pubblicazione: (2025)
• Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities–Involved High‐Risk Stratifications
  di: Yanqiu Xiong, et al.
  Pubblicazione: (2025)